



UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
OFFICE OF ADMINISTRATIVE LAW JUDGES

_____)
In the Matter of)
)
Otto Bock HealthCare North America, Inc.,)
)
a corporation,)
)
Respondent.)
_____)

Docket No. 9378

**ORDER ON RENEWED MOTION FOR
IN CAMERA TREATMENT**

I.

Pursuant to Rule 3.45(b) of the Commission’s Rules of Practice and the Scheduling Order entered in this matter, Respondent Otto Bock HealthCare North America, Inc. (“Ottobock”) filed a renewed motion for *in camera* treatment on August 7, 2018 (“August 7 Motion”). Ottobock seeks *in camera* treatment for portions of five trial exhibits. Respondent represents that Federal Trade Commission (“FTC” or “Commission”) Complaint Counsel has stated it does not plan to file an opposition.

For the reasons set forth below, the August 7 Motion is GRANTED.


II.

The July 2 Order on Respondent’s initial motion for *in camera* treatment sets forth the standards for *in camera* treatment by which the renewed motion is evaluated. Ottobock has supported its motion with a declaration from its Vice President of Medical Affairs, Government Affairs, and Future Development (“Ottobock Declaration”). The declaration describes in detail the confidential nature of the information contained in the documents, the competitive harm that Ottobock would suffer if this information were made publicly available, and the measures that Ottobock takes to ensure that the information contained in these documents remains confidential. The motion is tailored to seek *in camera* treatment for only those portions of the exhibits that contain highly sensitive information. The declaration explains that the exhibits contain: internal pricing, which reveals Respondent’s margins for certain products; current pricing and units sold

information; and Freedom Innovations' current business plans and new product development pipeline.

Respondent has met its burden of showing that the requested portions of the five exhibits meet the standard for *in camera* treatment. *In camera* treatment for a period of five years to expire on July 1, 2023 is granted for: PX1068, pages 024-041; PX1297, pages 024-025, 059-061; PX1518, pages 010, 015, 017; PX1524, pages 006-009; and PX1703, pages 009-010, 044-046.

ORDERED:



D. Michael Chappell
Chief Administrative Law Judge

Date: August 8, 2018